Low-dose administration of anti-PD-1 monoclonal antibodies could potentially reverse conditions associated with aging such as the accumulation of senescent cells and inflammation, according to a new study conducted at the Institute of Medical Science at the University of Tokyo. Read More
Investigators from 35Pharma Inc. carried out in vivo testing of HS-135, an activin-receptor-based fusion protein (ActRIIB ligand trap), focusing on target engagement, effect on body composition and efficacy in pulmonary arterial hypertension (PAH). Read More
Transcode Therapeutics Inc. has reported promising preclinical results with its immunotherapy candidate, TTX-siPDL1, in pancreatic adenocarcinoma. Read More
Researchers from Incyte Research Institute presented the discovery of a cyclin-dependent kinase 2 (CDK2) inhibitor, INCB-123667, being developed for the treatment of cyclin E dysregulated cancers. Read More
Small nuclear RNAs (snRNAs) play a crucial role in RNA splicing and cell functioning. The transcription of these RNAs is initiated by small nuclear RNA activation protein complex (SNAPc), and SNAPC4 is the subunit in charge of SNAPc-DNA binding. Previous studies have found that SNAPC4 deficiency led to decreased expression of these RNAs in animal models. Read More
Hamlet Pharma AB has shown that daily, long-term treatment with bovine α-lactalbumin made lethal to tumor cells (BAMLET) in drinking water inhibits intestinal tumor development in mice genetically susceptible to intestinal tumors, compared to mice not receiving BAMLET. Read More
Tuojie Biotech (Shanghai) Co. Ltd. has disclosed boric acid derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infections. Read More
Primary angle closure glaucoma (PACG) is characterized by anatomic blockage of the drainage angle of the eye leading to elevated eye pressure and optic neuropathy, and its molecular pathogenesis is still not well studied. Read More
Kinimmune Inc. has received US$400,000 in funding from the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for its phase I STTR application to advance the preclinical development of KIN-102, an immunostimulant for intratumoral injection that is designed to turn cold tumors hot for synergy with immuno-oncology drugs, such as checkpoint inhibitors. Read More
Humanwell Healthcare (Group) Co. Ltd. has synthesized dihydropyrimidoisoquinolinone derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, metabolic and endocrine disorders, among others. Read More
Qingdao Ruiji Medical Technology Co. Ltd. has identified benzofuran derivatives acting as farnesoid X receptor (FXR) agonists reported to be useful for the treatment of cancer, inflammation, metabolic, cardiovascular, liver, inflammatory bowel and renal diseases. Read More
The FDA has awarded orphan drug designation to Eikonoklastes Therapeutics Inc.'s ET-101 program for the treatment of amyotrophic lateral sclerosis (ALS). Read More
Boehringer Ingelheim Pharma GmbH & Co. KG has divulged imidazo[4,5-d]pyridazinonyl derivatives acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of cough, fibrosis, respiratory tract inflammation and idiopathic pulmonary fibrosis. Read More
Researchers from Washington University presented data from a study that aimed to identify myeloid-derived suppressor cell (MDSC) markers in patients with multiple sclerosis (MS). Read More
Bayer AG has described phosphorus derivatives acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer. Read More
